TNFSF11 and cancer: Of 821 subjects with two or more sequential measurements of RANKL and OPG, 697 subjects remained free of cancer during the 15-year follow-up, 19 women developed breast cancer, 16 men developed prostate cancer, and 89 other cancer types (all malignancies except for squamous-cell skin cancer).